CML-417: ASCEMBL Phase 3 Health-Related Quality of Life (HRQL) Comparison of Asciminib and Bosutinib for Patients with Chronic Myelogenous Leukemia in Chronic Phase (CML-CP), Previously Treated with 2 or More Tyrosine Kinase Inhibitors (TKI).

Autor: Mauro, Michael J., Boquimpani, Carla, Réa, Delphine, Hochhaus, Andreas, Maheshwari, Vikalp Kumar, Allepuz, Alex, Patwardhan, Pallavi, Ying Wu, DeRosa, Michael, Yosuke Minami
Zdroj: Clinical Lymphoma, Myeloma & Leukemia; 2021 Supplement 1, Vol. 21, pS336-S336, 1p
Databáze: Complementary Index
Externí odkaz: